PAUL D RUBIN
CIK 1210905 · Chief Medical Officer · last filed 2026-04-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$15.32M
Companies
3
Total Filings
57
Lifetime Open-Market Net
-$2.48M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BIOA | Chief Medical Officer | 5,437 | $18.04 | $98.1K | -$1.46M | 8 | 2026-04-03 |
| Viridian Therapeutics, Inc.\DE (MGEN) Delisted | EVP, Research & Development | — | — | — | $0 | 3 | 2019-02-08 |
| XOMA | Sr. VP Clinical Dev. & CMO | 364,217 | $41.79 | $15.22M | -$1.01M | 46 | 2016-03-22 |
Recent Filings · Page 6 of 6
57 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-07-23 | XOMA | Grant (A) | — | $0 | EDGAR |
| 2012-07-02 | XOMA | Mixed | −3,226 | $1.9K | EDGAR |
| 2012-05-25 | XOMA | Grant (A) | — | $0 | EDGAR |
| 2012-04-02 | XOMA | Exer (M) | +1,229 | $3.2K | EDGAR |
| 2012-02-14 | XOMA | Grant (A) | — | $0 | EDGAR |
| 2011-10-03 | XOMA | Exer (M) | +1,022 | $1.7K | EDGAR |
| 2011-06-02 | XOMA | Grant (A) | — | $0 | EDGAR |
Showing 51–57 of 57
Prev
Page 6 of 6
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.